Myriad Genetics (MYGN)
(Delayed Data from NSDQ)
$24.38 USD
-0.63 (-2.52%)
Updated May 21, 2024 04:00 PM ET
After-Market: $24.37 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MYGN 24.38 -0.63(-2.52%)
Will MYGN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for MYGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MYGN
Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Loss in Q1
Myriad (MYGN) Reports Q1 Earnings: What Key Metrics Have to Say
MYGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Myriad Genetics (MYGN) Reports Q1 Loss, Tops Revenue Estimates
Blueprint Medicines (BPMC) Reports Q1 Loss, Tops Revenue Estimates
Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline
Other News for MYGN
New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer
Insider Sale: President and CEO Paul Diaz Sells 227,844 Shares of Myriad Genetics Inc (MYGN)
Insider Sale: Director Lee Newcomer Sells 6,200 Shares of Myriad Genetics Inc (MYGN)
Myriad Genetics reports Prolaris Prostate Cancer Prognostic Test study published
What's Driving Twist Bioscience Corp's Surprising 20% Stock Rally?